Myriad Genetics (NASDAQ:MYGN) Releases FY25 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN - Get Free Report) updated its FY25 earnings guidance on Wednesday. The company provided EPS guidance of $0.07-0.11 for the period, compared to the consensus EPS estimate of $0.15. The company issued revenue guidance of $840-860 million, compared to the consensus revenue estimate of $879.47 million. Myriad Genetics also updated its FY 2025 guidance to 0.070-0.110 EPS.

Wall Street Analyst Weigh In

Several analysts have weighed in on MYGN shares. Piper Sandler dropped their price target on Myriad Genetics from $30.00 to $24.00 and set a "neutral" rating on the stock in a research note on Monday, November 11th. UBS Group initiated coverage on shares of Myriad Genetics in a research note on Tuesday, December 10th. They set a "neutral" rating and a $18.00 price objective on the stock. Morgan Stanley lowered their price target on shares of Myriad Genetics from $32.00 to $21.00 and set an "equal weight" rating on the stock in a report on Monday, November 18th. StockNews.com raised shares of Myriad Genetics from a "hold" rating to a "buy" rating in a report on Thursday, January 9th. Finally, Leerink Partners cut Myriad Genetics from an "outperform" rating to a "market perform" rating and reduced their price target for the stock from $30.00 to $21.00 in a report on Monday, December 9th. Three analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $24.27.

Myriad Genetics Stock Down 3.9 %

NASDAQ MYGN traded down $0.53 during trading hours on Wednesday, hitting $13.15. 853,375 shares of the company were exchanged, compared to its average volume of 873,184. The company has a 50 day moving average of $14.98 and a two-hundred day moving average of $22.10. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -10.12 and a beta of 1.89. Myriad Genetics has a 52-week low of $12.81 and a 52-week high of $29.30.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.